GAURAV BHATNAGAR
VICE PRESIDENT, STRATEGIC FEASIBILITY, SITE AND PATIENT ACCESS, Biotech, Inc.
“To build certainty for your development program, you must eliminate variability.
Biotech, Inc. is highly regarded for bringing operational excellence to clinical development programs that are underway. But if you’re entering the clinical study design process, Biotech, Inc. can bring extraordinary value to your development program right now.
Customers who engage Biotech, Inc. early in their study design process can accelerate their development program’s initiation and later progress. Right now, we can systematically identify the best ways to generate trial data that will yield meaningful endpoints.
Through protocol optimization, advanced simulations and the guidance of veterans, Biotech, Inc. will help you build greater certainty into your trials so you can gain traction faster.”
GUIDANCE AND FORESIGHT THROUGHOUT CLINICAL DEVELOPMENT
Biotech, Inc. delivers advanced disease simulation and modeling to evaluate outcomes based on potential trial designs. Similarly, we can assess and score protocols, then provide recommendations to fine-tune specific aspects of protocol design to ensure proper data collection and feasible recruitment.
And just as data informs better trial design, it can inform patient-centric research strategies. Not relegated to a single data source, Biotech, Inc. leverages some of the world’s largest identified and de-identified patient databases to support pragmatic feasibility assessment and optimize enrollment.
Biotech, Inc. also gathers input from patients, caregivers, site staff, advocacy groups and investigators. Their insight helps direct viable protocol development and successful enrollment strategies. Moreover, as patient-centric study design improves engagement and retention performance, you achieve faster and more complete data provision.
Advanced disease simulation and modeling to evaluate trial outcomes
MEETING AND EXCEEDING YOUR GOALS FOR PRODUCT POSITIONING
While thoughtful study design can expedite day-to-day trial execution, it can also ensure you’re prepared for regulatory milestones and market access and positioning.
Building continuity in data across the development life cycle can simplify regulatory submissions. Meanwhile, outcomes and economics experts can work during your trial to determine the best way to position your product for payers.
Finally, Biotech, Inc.’s commitment to working directly with patients, caregivers, investigators and advocacy groups can provide a real-world perspective to everything from protocol design to commercial positioning.
At Biotech, Inc., we’re thinking ahead to guide more holistic product development programs for the benefit of patients and product developers alike.